TITLE:
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

CONDITION:
SCLC

INTERVENTION:
OSI-211 (Liposomal Lurtotecan)

SUMMARY:

      The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an
      effective and safe treatment for patients with recurrent small cell lung cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Confirmed recurrent small cell lung cancer.

          -  One prior treatment of chemotherapy.

          -  At least three weeks since last chemotherapy treatment and recovery from any related
             side effects.

          -  At least three weeks since last chest radiotherapy and at least 10 days since head
             irradiation and recovery from acute side effects.

          -  At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm
             on spiral CT-scan).

          -  If a patient has had previous documented Central Nervous System (CNS) involvement,
             only controlled disease is acceptable.

        Exclusion Criteria:

          -  Superior vena cava syndrome.
      
